Key facts
- Cellares’s last known valuation is $675.0M (Aug 2023).
- It has raised $612.0M across 1 recorded rounds; the latest was Later Stage VC ($82.0M) in Apr 2021.
- Notable investors include 8VC, EDBI, Baillie Gifford, T. Rowe Price Group, Eclipse Capital — 16 tracked in total.
- Cellares has filed 1 Form D with the SEC, most recently May 2021 ($82.0M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Cellares
Funding rounds
1 roundsAbout Cellares
Operator of an integrated development and manufacturing organization intended for accelerating patients' access to life-saving cell therapies. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies, enabling academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, and meet global patient demand.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2019
- Employees
- 150
- Website
- cellares.com/
- Ownership
- Privately Held (backing)
Cellares doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellares shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellares in its N-PORT filings yet. We sweep new filings monthly.